Reported 23 days ago
Rogue Funds' first quarter 2025 investor letter highlights Achieve Life Sciences (NASDAQ: ACHV) amid a volatile investment landscape, reporting a significant loss but expressing confidence in its long-term potential following positive trial results. Despite the recent steep decline in share value, the firm suggests an impending rise post-NDA filing, predicting considerable upside for the stock if upcoming study results are favorable. However, they caution that AI stocks may offer more attractive returns in the short term.
Source: YAHOO